In total, Denmark-based Novo Nordisk has filed 21 lawsuits against medical spas, weight loss clinics and compounding pharmacies. The drugmaker accused these companies of selling illegal versions of semaglutide — the active ingredient of Ozempic, Rybelsus and Wegovy — that contain “known impurities and the presence of unknown impurities,” Novo Nordisk said in a May 30 statement.
Ozempic and Rybelsus are approved for Type 2 diabetes, and Wegovy is indicated for chronic weight management and serious cardiovascular events. All are blockbuster therapies, costing the U.S. healthcare system $38.6 billion in 2023.
Novo Nordisk said it does not sell bulk semaglutide to compounding pharmacies or any other entity. The company also does not contract external manufacturers to make the medications.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
